6 days Ago By ABMN Staff
Orion Portfolio Solutions LLC grew its position in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report ) by 42.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.
The institutional investor owned 16,486 shares of the biopharmaceutical company’s stock after purchasing an additional 4,933 shares during the period. Orion Portfolio Solutions LLC’s holdings in Ardelyx were worth $84,000 as of its most recent SEC filing. A number of other large investors also recently added to or reduced their stakes in ARDX.
EntryPoint Capital LLC boosted its stake in shares of Ardelyx by 103.2% in the fourth quarter. EntryPoint Capital LLC now owns 33,323 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 16,924 shares during the period.
Sheets Smith Investment Management purchased a new position in Ardelyx in the 4th quarter valued at approximately $58,000. Vanguard Group Inc. boosted its position in Ardelyx by 5.
6% in the 4th quarter. Vanguard Group Inc. now owns 14,362,659 shares of the biopharmaceutical company’s stock valued at $72,819,000 after buying an additional 767,111 shares during the period.
Fox Run Management L.L.C.
grew its stake in shares of Ardelyx by 214.5% in the fourth quarter. Fox Run Management L.
L.C. now owns 41,531 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 28,324 shares in the last quarter.
Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Ardelyx during the fourth quarter worth $254,000. 58.92% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity In other Ardelyx news, Director David M. Mott bought 199,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was acquired at an average price of $4.
99 per share, for a total transaction of $993,010.00. Following the completion of the purchase, the director now owns 1,937,765 shares of the company’s stock, valued at approximately $9,669,447.
35. This represents a 11.44 % increase in their ownership of the stock.
The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link . Also, insider Laura A. Williams sold 4,941 shares of the firm’s stock in a transaction dated Thursday, February 20th.
The stock was sold at an average price of $5.62, for a total value of $27,768.42.
Following the transaction, the insider now directly owns 303,804 shares in the company, valued at approximately $1,707,378.48. This represents a 1.
60 % decrease in their position. The disclosure for this sale can be found here . Over the last ninety days, insiders sold 158,076 shares of company stock valued at $823,804.
5.90% of the stock is currently owned by company insiders. Ardelyx Stock Performance Ardelyx ( NASDAQ:ARDX – Get Free Report ) last announced its earnings results on Thursday, February 20th.
The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02.
The firm had revenue of $116.13 million during the quarter, compared to analysts’ expectations of $111.16 million.
Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%.
As a group, analysts expect that Ardelyx, Inc. will post -0.18 earnings per share for the current year.
Wall Street Analyst Weigh In Several research analysts recently commented on ARDX shares. LADENBURG THALM/SH SH reissued a “buy” rating and set a $11.00 target price on shares of Ardelyx in a research note on Friday, March 7th.
Raymond James reaffirmed a “strong-buy” rating and issued a $13.00 target price (down previously from $15.00) on shares of Ardelyx in a report on Friday, February 21st.
BTIG Research assumed coverage on shares of Ardelyx in a research report on Tuesday, March 4th. They issued a “buy” rating and a $14.00 price objective on the stock.
Scotiabank started coverage on shares of Ardelyx in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective for the company.
Finally, Cantor Fitzgerald upgraded shares of Ardelyx to a “strong-buy” rating in a research note on Tuesday, March 4th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.
com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.61. Check Out Our Latest Analysis on Ardelyx Ardelyx Profile ( Free Report ) Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. See Also Want to see what other hedge funds are holding ARDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ardelyx, Inc.
( NASDAQ:ARDX – Free Report ). Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter .
.
